Member Info for Ghia

Dudio - I think you have drawn the wrong conclusion from the @home data.

“ more confirmation that Synairgen isn't right as a broad combatant of Covid”

The data did not suggest this the data actually suggested that the majority of patients who caught covid including those in the presumed vulnerable age range and risk factors would experience very mild symptoms.

Ergo you might as well give them something to mask the symptoms and let them get on with it themselves.

What the data did suggest is that there may be a way predicting at an early stage who is likely to need intervention and that SNG001 is a very effective drug at treating these patients in the home setting, as well as being effective at a later stage in the hospital setting.

Y-Alam - Tils never justified it’s £2 share price. In 6-12 months time perhaps it will justify £2 but not right now.

This is a good buy and hold opportunity but think 12months + on your investment.

Same I’ve contacted them but they have been very non-comital I miss the share centre.

Other shares in the fund have increased in value thus SNG are no longer 8% of the total fund value.

Strictly - that mentality will cost you. I suggest anyone contemplating this run a test.

Play with 10% of your holding and trade it.

Guarantee you will be better off holding, the real gains here will be made over night if you are out you miss out.

CG77 - I think the activ2 scenario is very simple.

We are being moved to P3, the Dr knows this is the case but no one has been dosed yet on P3 therefore SNG do not need to RNS.

SNG are well and truly on the home stretch some lab results against the delta variant would be very timely, pre-orders and rolling review off the back of an active2 move to P3 IMO.

Professor - whilst they are at it how about refusing to treat people who have smoked for lung damaged, people with diabetes due to poor diet, ivf for overweight couples, liver damage for alcoholics.

We live in a free society we should educate people to make smart choices rather than regulate people.

Don't forget that Activ2 is specifically measuring Viral Load as a primary outcome measure this should be very favourable for SNG.

This was not measured in the HT.

Covid hospital admissions on the rise again unfortunately.

Pharmacists can prescribe if they have done the required training 3 of my family members are prescribing pharmacists.

Normally the pharmacists catch the mistakes the dr’s make when prescribing drugs, the pharmacists understand the dosing levels much better than dr’s.

The dr’s have to know such a vast amount of knowledge especially gp’s that I wouldn’t expect them to get it right 100% of the time.

Jwd222 - Perhaps refrain from investing in the stock market if you cannot understand how to calculate basic things like market cap based on number of shares in issue multiplied by share price.

You are destined to loose a lot of money.

Matt - Really sorry to hear you are suffering with Long Covid wouldn't wish that upon anyone. I'd also like to point out my previous post was not me gleefully rubbing my hands together at the prospect of a large population suffering from long covid being the future customer base for the drug.

I'd much rather we had an effective treatment now preventing the damage being caused in the first place.

dgdg1 - I think at this point it would be useful to point out that SNG001 is not a treatment to tackle COPD.

It is an antiviral to assist fighting off viral infections which can cause people who suffer from COPD serious illness and or death.

A by product of the Covid pandemic is that there is an increasing population of Long Covid suffers who will most likely end up with COPD.

So the by product of Covid is that the already large population of COPD patients will only grow in years to come.

Could be any of the following:

- Progression of Active2 to phase 3
- Recruitment update on Sprinter P3 (final patient dosed Wishful thinking, could be DMC review data thus far?)
- Long Covid analysis, both HT and Hospital?
- Selection as one of 10 drugs to progress further by European agencies
- Curve ball application for EUA
- Curve ball pre-orders
- IV studies on indian variant
- JV or license Deal

Strictly - I beg to differ on that, nothing changed internally or external to the company to cause the drop.

None of our Institutions significantly reduced holdings that we are aware of.

Progress continued being made and globally covid is still very much a force to be reckoned with.

I personally think it was an easy call to make.

SNG certainly is a gift horse when it comes to making money.

Sub £1 was an easy buy >40% profit on those shares thank you very much.

I’m not a trader I prefer to buy and hold.

P2 to P3 transition is brewing, would be very interesting if they drop placebo for P3 and make it drug to drug comparison for all treatments that progress. I have a feeling we would fare very favourably in that situation.

Everup - The issue is blockchain is not really diversification when the entire crypto market moves in tandem.

Schrow - One thing that is evident Polar and Polygon chose to wait it out as holders rather than sit on the sidelines.

This drop has mainly been retail driven a few months and our fortunes will be reversed IMO.

Those numbers are most likely a result of the lack of testing early on in the crisis.

There was a much higher infection rate than testing could identify thus the assumed hospitalisation rate was higher.

Subsequently we have tested in higher numbers hence the true hospitalisation rate has decreased.